Journal profile · Oncology
Anticancer Research
ISSN 0250-7005 · eISSN 1791-7530 · International Institute of Anticancer Research · GREECE · Bimonthly · Founded 1981
Anticancer Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.83; hybrid open access; median 29 days to acceptance (138 articles, last 24 months); community-reported acceptance: about 35%; 539 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Anticancer Research is published by International Institute of Anticancer Research and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment and Gastric Cancer Management and Outcomes, together about 17.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine6.7%
- Esophageal Cancer Research and TreatmentMedicine5.2%
- Gastric Cancer Management and OutcomesMedicine5.2%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine5.2%
- Inflammatory Biomarkers in Disease PrognosisMedicine5%
- Cancer Cells and MetastasisMedicine4.9%
- Head and Neck Cancer StudiesMedicine4.9%
- Pancreatic and Hepatic Oncology ResearchMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.83LetPub ·
- CiteScore 2026-06
- 3.4LetPub ·
- SJR 2026-06
- 0.58LetPub ·
- SNIP 2026-06
- 0.62LetPub ·
- h-index
- 110LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 2,761OpenAlex ·
- 2-year mean citedness
- 1.6OpenAlex ·
- Self-citation rate
- 11.1%LetPub ·
- Share of gold OA articles
- 31.9%LetPub ·
Volume
- Articles per year
- 479LetPub ·
Articles by year OpenAlex count · 7,537 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 412 | 117 | 60 |
| 2025 | 539 | 216 | 548 |
| 2024 | 597 | 226 | 1,863 |
| 2023 | 643 | 425 | 2,919 |
| 2022 | 669 | 281 | 4,886 |
| 2021 | 787 | 615 | 6,789 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
29 daysMedian, submission to acceptance · P25–P75 22 days – 39 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 138 articles with submission and acceptance dates (1,130 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 35%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- International Institute of Anticancer Research
- Country or region
- GREECE
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1981
- ISSN
- 0250-7005
- Electronic ISSN
- 1791-7530
- Latest issue on the website
- Volume 46, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Anticancer Research
What CAS zone is Anticancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Anticancer Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Anticancer Research?
The latest impact factor listed by LetPub is 1.83; CiteScore 3.4, h-index 79.
How long does peer review take at Anticancer Research?
Based on the dates recorded on 138 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 29 days (interquartile range 22–39 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 35%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Anticancer Research?
According to LetPub and DOAJ records, Anticancer Research is indexed in SCIE and Scopus.
Is Anticancer Research open access, and what is the APC?
Anticancer Research is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .